<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258101</url>
  </required_header>
  <id_info>
    <org_study_id>ML17087</org_study_id>
    <nct_id>NCT01258101</nct_id>
  </id_info>
  <brief_title>A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3</brief_title>
  <official_title>Randomized, Multicenter Study to Compare the Efficacy of Pegylated Interferon Alfa (PEG-IFN) in Combination With Two Different Doses of Ribavirin in Patients With Chronic Hepatitis C and Subtype 2/3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, parallel arm study will evaluate the efficacy and safety of Pegasys
      (peginterferon alfa-2a) in combination with 2 different doses of ribavirin in patients with
      chronic hepatitis C, genotype 2 or 3. Patients will be randomized to 4 treatment groups
      receiving Pegasys (180 mcg subcutaneously weekly) for either 16 or 24 weeks with one of two
      doses of ribavirin (400 mg or 800 mg orally daily). The anticipated time on study treatment
      is 16 or 24 weeks with a 24-week follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment</measure>
    <time_frame>Up to Week 48 (24 weeks post completion of the treatment)</time_frame>
    <description>Sustained virological response was defined as the percentage of participants in each group with undetectable Hepatitis C virus-Ribonucleic acid (HCV-RNA) measurement at 24 weeks post completion of the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hepatitis C Virus-RNA Determined by AMPLICOR HCV Test At Week 24 and Week 48</measure>
    <time_frame>At Week 24 and Week 48</time_frame>
    <description>Serum Hepatitis C Virus-RNA (HCV-RNA) was done by Polymerase chain reaction (PCR). Samples for a qualitative PCR (AMPLICOR® HCV Test v2.0) were obtained at Week 24 and Week 48. 'G2' and 'G3' indicates Genotype 2 and Genotype 3 respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virological Response at the End of the Treatment</measure>
    <time_frame>At Week 16 and Week 24</time_frame>
    <description>Virological response at the end of the treatment (ETR) was defined as the percentage of participants with negative qualitative PCR in each group at completion of the treatment. ETR is defined as Week 16 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response Rates as Per Genotype at End of Treatment</measure>
    <time_frame>At Week 16 and Week 24</time_frame>
    <description>Virologic Response was defined as undetectable HCV-RNA levels (determined by AMPLICOR HCV test) at Week 16 and Week 24. Virologic response rates based on genotype (G2 and G3) were reported. ETR is defined as Week 16 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Events and Any Serious Adverse Events</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Hemoglobin Levels at End of Treatment</measure>
    <time_frame>At Week 16 and Week 24</time_frame>
    <description>Hemoglobin (Hb) levels at end of treatment (Week 16 and Week 24) were reported. The mean lowest Hb value after treatment starts with a median of 129 gram (g)/Litre (L). The far most frequent hemoglobin class was &gt;=100 g/L. The purpose of assessing the Hb levels is associated with ribavirin dose. The primary toxicity of ribavirin dose (1000-1200 mg/day, maximum tolerated dose) is anemia with a reduction in hemoglobin levels generally occurring within the first 1-2 weeks of initiating therapy. Decreases in hemoglobin seen in the combination treatment of ribavirin and Interferon-alfa are managed with reduction in ribavirin dosage to 600 mg/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SF-36 Scores at Baseline and Weeks 16, 24 and 48</measure>
    <time_frame>At Baseline (Week 0) and Weeks 16, 24 and 48</time_frame>
    <description>Short-Form Health Survey (SF-36) is a 36-item questionnaire measuring eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Where Baseline (BS) is Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean FSS Scores at Baseline and Weeks 16, 24 and 48</measure>
    <time_frame>At Baseline (Week 0) and Weeks 16, 24 and 48</time_frame>
    <description>The Fatigue Severity Scale (FSS) is a self-administered instrument that includes 9 items rated on a 7-point scale, measuring fatigue severity. The participants were asked to score each statement, based on how the statement applied to them over the preceding week. The fatigue severity score is the average of the scores on the 9 questions; scores range from 1-7, with lower scores indicating less fatigue. Baseline is defined as Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Beschwerdeliste Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 16, 24 and 48</measure>
    <time_frame>At Baseline (Week 0) and Weeks 16, 24 and 48</time_frame>
    <description>Psychiatric assessment were performed using Beschwerdeliste (BL) questionnaires. BL results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. The BL questionnaire items were scored by calculating the average response to all answered items. Items were graded 1=&quot;stark&quot; (affliction is strong) to 4=&quot;gar nicht&quot; (not present). The higher the BL score, the less afflictions were present for a participant. Baseline is defined as Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory Mean Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 4, 8, 12, 24 and 48</measure>
    <time_frame>At Baseline (Week 0) and Weeks 4, 8, 12, 24 and 48</time_frame>
    <description>For the psychiatric assessment, the results of the Beck Depression Inventory (BDI) questionnaires were evaluated. BDI results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. BDI is 21 item participant rated inventory evaluates depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicates more depression. Mean scores are presented by visit. Baseline is defined as Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Viral Response</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Time to viral response was calculated as Date of first negative PCR result after screening - date of PCR screening sample + 1 [in days]. Mean of number of days to viral response for overall population were reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Peginterferon/Ribavirin 800 mg (24 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon/Ribavirin 400 mg (24 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon/Ribavirin 800 mg (16 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon/Ribavirin 400 mg (16 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc weekly, 24 weeks</description>
    <arm_group_label>Peginterferon/Ribavirin 800 mg (24 Weeks)</arm_group_label>
    <arm_group_label>Peginterferon/Ribavirin 400 mg (24 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc weekly, 16 weeks</description>
    <arm_group_label>Peginterferon/Ribavirin 800 mg (16 Weeks)</arm_group_label>
    <arm_group_label>Peginterferon/Ribavirin 400 mg (16 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>800 mg orally daily</description>
    <arm_group_label>Peginterferon/Ribavirin 800 mg (24 Weeks)</arm_group_label>
    <arm_group_label>Peginterferon/Ribavirin 800 mg (16 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>400 mg orally daily</description>
    <arm_group_label>Peginterferon/Ribavirin 400 mg (24 Weeks)</arm_group_label>
    <arm_group_label>Peginterferon/Ribavirin 400 mg (16 Weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, 18-65 years of age

          -  Chronic hepatitis C, genotype 2 or 3

          -  Positive HCV RNA level in serum at screening (COBAS AMPLICOR MONITOR HCV test)

          -  Abdominal sonography within 3 months prior to study start

        Exclusion Criteria:

          -  Previous interferon and/or pegylated interferon and ribavirin therapy

          -  Liver cirrhosis, class B or C (Child-Pugh)

          -  Systemic anti-neoplastic or immunomodulatory treatment &lt;=6 months before study drug

          -  History or evidence of medical condition associated with chronic liver disease other
             than chronic hepatitis C

          -  Decompensated liver disease

          -  Positive for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gratwein</city>
        <zip>8112</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberndorf</city>
        <zip>5110</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ried-innkreis</city>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <results_first_submitted>January 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>May 30, 2016</last_update_submitted>
  <last_update_submitted_qc>May 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 395 participants were recruited at 20 centres in Austria in the study conducted from 20 May 2003 to 10 July 2008.</recruitment_details>
      <pre_assignment_details>Of the 395 participants, 380 were randomized to treatment groups. A total of 15 participants were screening failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
          <description>Eligible participants were administered peginterferon alfa-2a (PEG-IFNα-2a) 180 microgram (mcg) subcutaneously (SC) once weekly + Ribavirin 800 milligram (mg) orally daily for 24 weeks (W). The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="P2">
          <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="P3">
          <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="P4">
          <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Population</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Standard Analysis Population</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Extra exclusion criterion amended</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Informed consent has been withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient is not able to attend visits</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient´s compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PCR positive at week 24</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="B3">
          <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="B4">
          <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="380"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="11.1"/>
                    <measurement group_id="B2" value="35.7" spread="10.2"/>
                    <measurement group_id="B3" value="35.8" spread="11.2"/>
                    <measurement group_id="B4" value="35.2" spread="10.0"/>
                    <measurement group_id="B5" value="36.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment</title>
        <description>Sustained virological response was defined as the percentage of participants in each group with undetectable Hepatitis C virus-Ribonucleic acid (HCV-RNA) measurement at 24 weeks post completion of the treatment.</description>
        <time_frame>Up to Week 48 (24 weeks post completion of the treatment)</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment</title>
          <description>Sustained virological response was defined as the percentage of participants in each group with undetectable Hepatitis C virus-Ribonucleic acid (HCV-RNA) measurement at 24 weeks post completion of the treatment.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="72.5" upper_limit="87.6"/>
                    <measurement group_id="O2" value="78.2" lower_limit="69.3" upper_limit="85.5"/>
                    <measurement group_id="O3" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O4" value="61.5" lower_limit="40.6" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to Arms Peginterferon/Ribavirin 800 mg (16 weeks) and Peginterferon/Ribavirin 400 mg (16 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>32.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.5</ci_lower_limit>
            <ci_upper_limit>53.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (24 weeks) and Peginterferon/Ribavirin 400 mg (24 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (24 weeks) and Peginterferon/Ribavirin 800 mg (16 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>19.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (24 weeks) and Peginterferon/Ribavirin 400 mg (16 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-21.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.2</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hepatitis C Virus-RNA Determined by AMPLICOR HCV Test At Week 24 and Week 48</title>
        <description>Serum Hepatitis C Virus-RNA (HCV-RNA) was done by Polymerase chain reaction (PCR). Samples for a qualitative PCR (AMPLICOR® HCV Test v2.0) were obtained at Week 24 and Week 48. 'G2' and 'G3' indicates Genotype 2 and Genotype 3 respectively.</description>
        <time_frame>At Week 24 and Week 48</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis C Virus-RNA Determined by AMPLICOR HCV Test At Week 24 and Week 48</title>
          <description>Serum Hepatitis C Virus-RNA (HCV-RNA) was done by Polymerase chain reaction (PCR). Samples for a qualitative PCR (AMPLICOR® HCV Test v2.0) were obtained at Week 24 and Week 48. 'G2' and 'G3' indicates Genotype 2 and Genotype 3 respectively.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2, W24, HCV-RNA Positive (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="24.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24, HCV-RNA Negative (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W48, HCV-RNA Positive (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                    <measurement group_id="O2" value="23.1" lower_limit="5.0" upper_limit="53.8"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O4" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W48, HCV-RNA Negative (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                    <measurement group_id="O2" value="76.9" lower_limit="46.2" upper_limit="95.0"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O4" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24, HCV-RNA Positive (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.6" upper_limit="8.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24, HCV-RNA Negative (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.6" upper_limit="100"/>
                    <measurement group_id="O2" value="96.9" lower_limit="91.2" upper_limit="99.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, HCV-RNA Positive (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="13.4" upper_limit="30.0"/>
                    <measurement group_id="O2" value="21.6" lower_limit="13.9" upper_limit="31.2"/>
                    <measurement group_id="O3" value="11.1" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O4" value="39.1" lower_limit="19.7" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, HCV-RNA Negative (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="70.0" upper_limit="86.6"/>
                    <measurement group_id="O2" value="78.4" lower_limit="68.8" upper_limit="86.1"/>
                    <measurement group_id="O3" value="88.9" lower_limit="65.3" upper_limit="98.6"/>
                    <measurement group_id="O4" value="60.9" lower_limit="38.5" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virological Response at the End of the Treatment</title>
        <description>Virological response at the end of the treatment (ETR) was defined as the percentage of participants with negative qualitative PCR in each group at completion of the treatment. ETR is defined as Week 16 and Week 24.</description>
        <time_frame>At Week 16 and Week 24</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virological Response at the End of the Treatment</title>
          <description>Virological response at the end of the treatment (ETR) was defined as the percentage of participants with negative qualitative PCR in each group at completion of the treatment. ETR is defined as Week 16 and Week 24.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="93.9" upper_limit="99.8"/>
                    <measurement group_id="O2" value="97.3" lower_limit="92.2" upper_limit="99.4"/>
                    <measurement group_id="O3" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100" lower_limit="86.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (16 weeks) and Peginterferon/Ribavirin 400 mg (16 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (24 weeks) and Peginterferon/Ribavirin 400 mg (24 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (24 weeks) and Peginterferon/Ribavirin 800 mg (16 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis was applied to arms Peginterferon/Ribavirin 800 mg (24 weeks) and Peginterferon/Ribavirin 400 mg (16 weeks).</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response Rates as Per Genotype at End of Treatment</title>
        <description>Virologic Response was defined as undetectable HCV-RNA levels (determined by AMPLICOR HCV test) at Week 16 and Week 24. Virologic response rates based on genotype (G2 and G3) were reported. ETR is defined as Week 16 and Week 24.</description>
        <time_frame>At Week 16 and Week 24</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response Rates as Per Genotype at End of Treatment</title>
          <description>Virologic Response was defined as undetectable HCV-RNA levels (determined by AMPLICOR HCV test) at Week 16 and Week 24. Virologic response rates based on genotype (G2 and G3) were reported. ETR is defined as Week 16 and Week 24.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2, W16, Virologic Response (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O4" value="100" lower_limit="29.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24, Virologic Response (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W16,Virologic Response (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="85.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24,Virologic Response (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.6" upper_limit="100"/>
                    <measurement group_id="O2" value="96.9" lower_limit="91.2" upper_limit="99.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Events and Any Serious Adverse Events</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>The Safety analysis population was defined to include only participants who received at least one dose of (either) study medication and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events and Any Serious Adverse Events</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
          <population>The Safety analysis population was defined to include only participants who received at least one dose of (either) study medication and had at least one post-baseline assessment.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Hemoglobin Levels at End of Treatment</title>
        <description>Hemoglobin (Hb) levels at end of treatment (Week 16 and Week 24) were reported. The mean lowest Hb value after treatment starts with a median of 129 gram (g)/Litre (L). The far most frequent hemoglobin class was &gt;=100 g/L. The purpose of assessing the Hb levels is associated with ribavirin dose. The primary toxicity of ribavirin dose (1000-1200 mg/day, maximum tolerated dose) is anemia with a reduction in hemoglobin levels generally occurring within the first 1-2 weeks of initiating therapy. Decreases in hemoglobin seen in the combination treatment of ribavirin and Interferon-alfa are managed with reduction in ribavirin dosage to 600 mg/day.</description>
        <time_frame>At Week 16 and Week 24</time_frame>
        <population>The Safety analysis population was defined to include only participant who received at least one dose of (either) study medication and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Hemoglobin Levels at End of Treatment</title>
          <description>Hemoglobin (Hb) levels at end of treatment (Week 16 and Week 24) were reported. The mean lowest Hb value after treatment starts with a median of 129 gram (g)/Litre (L). The far most frequent hemoglobin class was &gt;=100 g/L. The purpose of assessing the Hb levels is associated with ribavirin dose. The primary toxicity of ribavirin dose (1000-1200 mg/day, maximum tolerated dose) is anemia with a reduction in hemoglobin levels generally occurring within the first 1-2 weeks of initiating therapy. Decreases in hemoglobin seen in the combination treatment of ribavirin and Interferon-alfa are managed with reduction in ribavirin dosage to 600 mg/day.</description>
          <population>The Safety analysis population was defined to include only participant who received at least one dose of (either) study medication and had at least one post-baseline safety assessment.</population>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.00" lower_limit="116.00" upper_limit="134.00"/>
                    <measurement group_id="O2" value="131.00" lower_limit="120.50" upper_limit="140.00"/>
                    <measurement group_id="O3" value="129.50" lower_limit="116.00" upper_limit="140.50"/>
                    <measurement group_id="O4" value="131.00" lower_limit="124.00" upper_limit="143.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.00" lower_limit="115.00" upper_limit="133.00"/>
                    <measurement group_id="O2" value="130.00" lower_limit="121.00" upper_limit="140.00"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean SF-36 Scores at Baseline and Weeks 16, 24 and 48</title>
        <description>Short-Form Health Survey (SF-36) is a 36-item questionnaire measuring eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Where Baseline (BS) is Week 0.</description>
        <time_frame>At Baseline (Week 0) and Weeks 16, 24 and 48</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean SF-36 Scores at Baseline and Weeks 16, 24 and 48</title>
          <description>Short-Form Health Survey (SF-36) is a 36-item questionnaire measuring eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Where Baseline (BS) is Week 0.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2, BS, Physical Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" spread="22.1"/>
                    <measurement group_id="O2" value="87.9" spread="12.9"/>
                    <measurement group_id="O3" value="76.7" spread="10.4"/>
                    <measurement group_id="O4" value="69.4" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W16, Physical Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="63.3" spread="20.8"/>
                    <measurement group_id="O4" value="63.3" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24 Physical Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="20.7"/>
                    <measurement group_id="O2" value="79.0" spread="17.9"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48, Physical Functioning, (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" spread="30.3"/>
                    <measurement group_id="O2" value="81.0" spread="20.6"/>
                    <measurement group_id="O3" value="82.5" spread="17.7"/>
                    <measurement group_id="O4" value="85.0" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BS, Physical Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" spread="13.9"/>
                    <measurement group_id="O2" value="85.9" spread="18.3"/>
                    <measurement group_id="O3" value="87.2" spread="15.2"/>
                    <measurement group_id="O4" value="77.9" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W16, Physical Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="81.1" spread="14.5"/>
                    <measurement group_id="O4" value="69.8" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24, Physical Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="20.8"/>
                    <measurement group_id="O2" value="79.8" spread="22.5"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, Physical Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="13.8"/>
                    <measurement group_id="O2" value="89.7" spread="18.6"/>
                    <measurement group_id="O3" value="88.9" spread="12.9"/>
                    <measurement group_id="O4" value="87.9" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BS,Role Functioning Physical (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="38.4"/>
                    <measurement group_id="O2" value="88.9" spread="22.0"/>
                    <measurement group_id="O3" value="75.0" spread="25.0"/>
                    <measurement group_id="O4" value="50.0" spread="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16,Role Functioning Physical (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="16.7" spread="28.9"/>
                    <measurement group_id="O4" value="41.7" spread="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W24,Role Functioning Physical (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="31.3"/>
                    <measurement group_id="O2" value="50.0" spread="37.3"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48,Role Functioning Physical (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" spread="47.7"/>
                    <measurement group_id="O2" value="88.9" spread="18.2"/>
                    <measurement group_id="O3" value="87.5" spread="17.7"/>
                    <measurement group_id="O4" value="87.5" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BS,Role Functioning Physical (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="30.7"/>
                    <measurement group_id="O2" value="73.9" spread="33.0"/>
                    <measurement group_id="O3" value="83.3" spread="28.0"/>
                    <measurement group_id="O4" value="75.0" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W16,Role Functioning Physical (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="61.1" spread="35.6"/>
                    <measurement group_id="O4" value="61.8" spread="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W24,Role Functioning Physical (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="40.4"/>
                    <measurement group_id="O2" value="63.6" spread="39.5"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W48,Role Functioning Physical (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" spread="23.9"/>
                    <measurement group_id="O2" value="85.5" spread="30.2"/>
                    <measurement group_id="O3" value="91.7" spread="17.7"/>
                    <measurement group_id="O4" value="81.3" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BS, Bodily Pain (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="29.0"/>
                    <measurement group_id="O2" value="83.0" spread="24.5"/>
                    <measurement group_id="O3" value="71.0" spread="25.7"/>
                    <measurement group_id="O4" value="61.0" spread="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16, Bodily Pain (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="61.3" spread="39.0"/>
                    <measurement group_id="O4" value="54.3" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24, Bodily Pain (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="28.5"/>
                    <measurement group_id="O2" value="55.5" spread="33.3"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W48, Bodily Pain (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="33.7"/>
                    <measurement group_id="O2" value="84.0" spread="15.6"/>
                    <measurement group_id="O3" value="81.0" spread="26.9"/>
                    <measurement group_id="O4" value="81.0" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BS, Bodily Pain (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" spread="22.0"/>
                    <measurement group_id="O2" value="82.9" spread="19.7"/>
                    <measurement group_id="O3" value="73.0" spread="26.1"/>
                    <measurement group_id="O4" value="83.6" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W16, Bodily Pain (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="69.6" spread="19.4"/>
                    <measurement group_id="O4" value="70.2" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24, Bodily Pain(n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="27.3"/>
                    <measurement group_id="O2" value="71.5" spread="25.9"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W48, Bodily Pain (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" spread="19.2"/>
                    <measurement group_id="O2" value="87.7" spread="23.0"/>
                    <measurement group_id="O3" value="84.1" spread="18.1"/>
                    <measurement group_id="O4" value="81.9" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BS, General Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="9.3"/>
                    <measurement group_id="O2" value="66.3" spread="17.6"/>
                    <measurement group_id="O3" value="62.3" spread="21.1"/>
                    <measurement group_id="O4" value="51.0" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16,General Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="42.3" spread="27.5"/>
                    <measurement group_id="O4" value="49.0" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24, General Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="12.7"/>
                    <measurement group_id="O2" value="67.2" spread="20.5"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48, General Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="13.4"/>
                    <measurement group_id="O2" value="76.0" spread="14.9"/>
                    <measurement group_id="O3" value="53.5" spread="26.2"/>
                    <measurement group_id="O4" value="43.5" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BS, General Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="18.5"/>
                    <measurement group_id="O2" value="61.7" spread="19.4"/>
                    <measurement group_id="O3" value="56.9" spread="12.9"/>
                    <measurement group_id="O4" value="61.1" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W16, General Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="58.3" spread="20.4"/>
                    <measurement group_id="O4" value="63.6" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24, General Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" spread="18.1"/>
                    <measurement group_id="O2" value="59.5" spread="21.3"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, General Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="16.0"/>
                    <measurement group_id="O2" value="70.5" spread="21.6"/>
                    <measurement group_id="O3" value="70.2" spread="19.5"/>
                    <measurement group_id="O4" value="63.0" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BS, Vitality (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" spread="20.5"/>
                    <measurement group_id="O2" value="62.2" spread="11.4"/>
                    <measurement group_id="O3" value="43.3" spread="18.9"/>
                    <measurement group_id="O4" value="35.0" spread="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16, Vitality (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="25.0" spread="21.8"/>
                    <measurement group_id="O4" value="30.6" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24, Vitality (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="23.0"/>
                    <measurement group_id="O2" value="39.5" spread="22.0"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48, Vitality (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" spread="19.3"/>
                    <measurement group_id="O2" value="63.9" spread="15.0"/>
                    <measurement group_id="O3" value="57.5" spread="24.7"/>
                    <measurement group_id="O4" value="45.0" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BS, Vitality (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="21.1"/>
                    <measurement group_id="O2" value="51.9" spread="21.4"/>
                    <measurement group_id="O3" value="51.7" spread="24.9"/>
                    <measurement group_id="O4" value="49.4" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W16, Vitality (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="46.1" spread="19.5"/>
                    <measurement group_id="O4" value="43.5" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W24, Vitality (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="24.4"/>
                    <measurement group_id="O2" value="45.5" spread="23.8"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, Vitality (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="19.1"/>
                    <measurement group_id="O2" value="58.7" spread="20.2"/>
                    <measurement group_id="O3" value="70.6" spread="15.7"/>
                    <measurement group_id="O4" value="60.1" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BS, Social Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" spread="21.8"/>
                    <measurement group_id="O2" value="93.8" spread="10.6"/>
                    <measurement group_id="O3" value="75.0" spread="12.5"/>
                    <measurement group_id="O4" value="56.3" spread="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W16, Social Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="50.0" spread="43.3"/>
                    <measurement group_id="O4" value="58.3" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W24, Social Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" spread="32.0"/>
                    <measurement group_id="O2" value="76.3" spread="28.5"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48, Social Functioning (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" spread="15.6"/>
                    <measurement group_id="O2" value="86.1" spread="15.9"/>
                    <measurement group_id="O3" value="81.3" spread="26.5"/>
                    <measurement group_id="O4" value="81.3" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BS, Social Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" spread="19.5"/>
                    <measurement group_id="O2" value="77.2" spread="23.5"/>
                    <measurement group_id="O3" value="86.1" spread="20.2"/>
                    <measurement group_id="O4" value="84.7" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W16, Social Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="63.9" spread="20.2"/>
                    <measurement group_id="O4" value="66.9" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W24, Social Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="26.7"/>
                    <measurement group_id="O2" value="72.1" spread="26.3"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, Social Functioning (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" spread="21.0"/>
                    <measurement group_id="O2" value="81.6" spread="27.0"/>
                    <measurement group_id="O3" value="87.5" spread="18.8"/>
                    <measurement group_id="O4" value="78.7" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BS, Role Functioning Emotional (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="36.4"/>
                    <measurement group_id="O2" value="88.9" spread="23.6"/>
                    <measurement group_id="O3" value="77.8" spread="19.2"/>
                    <measurement group_id="O4" value="50.0" spread="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16, Role Functioning Emotional (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="33.3" spread="33.3"/>
                    <measurement group_id="O4" value="44.4" spread="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W24, Role Functioning Emotional (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="38.7"/>
                    <measurement group_id="O2" value="43.3" spread="38.7"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48, Role Functioning Emotional (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="37.7"/>
                    <measurement group_id="O2" value="85.2" spread="24.2"/>
                    <measurement group_id="O3" value="100.0" spread="0.0"/>
                    <measurement group_id="O4" value="83.3" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BS,Role Functioning Emotional (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="29.7"/>
                    <measurement group_id="O2" value="73.2" spread="36.1"/>
                    <measurement group_id="O3" value="70.4" spread="35.1"/>
                    <measurement group_id="O4" value="68.5" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W16,Role Functioning Emotional (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="63.0" spread="35.1"/>
                    <measurement group_id="O4" value="60.8" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W24,Role Functioning Emotional (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="41.0"/>
                    <measurement group_id="O2" value="57.4" spread="44.6"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W48,Role Functioning Emotional (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="23.8"/>
                    <measurement group_id="O2" value="84.2" spread="33.4"/>
                    <measurement group_id="O3" value="88.9" spread="23.6"/>
                    <measurement group_id="O4" value="79.2" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BS, Mental Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" spread="13.5"/>
                    <measurement group_id="O2" value="73.2" spread="14.9"/>
                    <measurement group_id="O3" value="57.3" spread="18.0"/>
                    <measurement group_id="O4" value="58.0" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16, Mental Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="42.7" spread="20.1"/>
                    <measurement group_id="O4" value="49.3" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W24, Mental Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="22.5"/>
                    <measurement group_id="O2" value="64.8" spread="21.2"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48, Mental Health (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" spread="19.2"/>
                    <measurement group_id="O2" value="76.1" spread="14.3"/>
                    <measurement group_id="O3" value="58.5" spread="37.5"/>
                    <measurement group_id="O4" value="70.0" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BS, Mental Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" spread="16.6"/>
                    <measurement group_id="O2" value="67.8" spread="17.2"/>
                    <measurement group_id="O3" value="63.6" spread="17.4"/>
                    <measurement group_id="O4" value="59.6" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W16, Mental Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="56.4" spread="15.0"/>
                    <measurement group_id="O4" value="55.5" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W24, Mental Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="19.9"/>
                    <measurement group_id="O2" value="63.2" spread="21.0"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48, Mental Health (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="15.7"/>
                    <measurement group_id="O2" value="68.8" spread="20.9"/>
                    <measurement group_id="O3" value="68.0" spread="20.2"/>
                    <measurement group_id="O4" value="64.1" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BS,Reported Health Transition (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.5"/>
                    <measurement group_id="O2" value="3.0" spread="0.8"/>
                    <measurement group_id="O3" value="3.7" spread="0.6"/>
                    <measurement group_id="O4" value="3.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W16,Reported Health Transition (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="4.0" spread="1.0"/>
                    <measurement group_id="O4" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W24,Reported Health Transition (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.0"/>
                    <measurement group_id="O2" value="3.7" spread="0.8"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,W48,Reported Health Transition (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="1.9" spread="0.8"/>
                    <measurement group_id="O3" value="2.0" spread="0.0"/>
                    <measurement group_id="O4" value="2.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BS,Reported Health Transition (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.1"/>
                    <measurement group_id="O2" value="2.9" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="0.9"/>
                    <measurement group_id="O4" value="2.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W16,Reported Health Transition (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O3" value="3.3" spread="1.1"/>
                    <measurement group_id="O4" value="2.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W24,Reported Health Transition (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.3"/>
                    <measurement group_id="O2" value="2.7" spread="1.4"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a SF36 assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,W48,Reported Health Transition (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.9"/>
                    <measurement group_id="O2" value="1.9" spread="1.1"/>
                    <measurement group_id="O3" value="2.3" spread="1.2"/>
                    <measurement group_id="O4" value="2.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean FSS Scores at Baseline and Weeks 16, 24 and 48</title>
        <description>The Fatigue Severity Scale (FSS) is a self-administered instrument that includes 9 items rated on a 7-point scale, measuring fatigue severity. The participants were asked to score each statement, based on how the statement applied to them over the preceding week. The fatigue severity score is the average of the scores on the 9 questions; scores range from 1-7, with lower scores indicating less fatigue. Baseline is defined as Week 0.</description>
        <time_frame>At Baseline (Week 0) and Weeks 16, 24 and 48</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean FSS Scores at Baseline and Weeks 16, 24 and 48</title>
          <description>The Fatigue Severity Scale (FSS) is a self-administered instrument that includes 9 items rated on a 7-point scale, measuring fatigue severity. The participants were asked to score each statement, based on how the statement applied to them over the preceding week. The fatigue severity score is the average of the scores on the 9 questions; scores range from 1-7, with lower scores indicating less fatigue. Baseline is defined as Week 0.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2, BS (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.2"/>
                    <measurement group_id="O2" value="3.4" spread="1.1"/>
                    <measurement group_id="O3" value="4.9" spread="0.3"/>
                    <measurement group_id="O4" value="3.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W16 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                    <measurement group_id="O3" value="6.2" spread="0.5"/>
                    <measurement group_id="O4" value="3.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W24 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.3"/>
                    <measurement group_id="O2" value="4.4" spread="1.2"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, W48 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.6"/>
                    <measurement group_id="O2" value="3.5" spread="1.2"/>
                    <measurement group_id="O3" value="4.5" spread="0.4"/>
                    <measurement group_id="O4" value="3.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BS(n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.2"/>
                    <measurement group_id="O2" value="3.8" spread="1.6"/>
                    <measurement group_id="O3" value="3.4" spread="1.5"/>
                    <measurement group_id="O4" value="3.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W16, (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                    <measurement group_id="O2" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                    <measurement group_id="O3" value="4.0" spread="1.6"/>
                    <measurement group_id="O4" value="4.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W24 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.7"/>
                    <measurement group_id="O2" value="4.1" spread="1.7"/>
                    <measurement group_id="O3" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">The Protocol (and therefore the SAP) had not planned a FSS assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, W48 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.3"/>
                    <measurement group_id="O2" value="3.2" spread="1.6"/>
                    <measurement group_id="O3" value="2.4" spread="1.6"/>
                    <measurement group_id="O4" value="3.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Beschwerdeliste Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 16, 24 and 48</title>
        <description>Psychiatric assessment were performed using Beschwerdeliste (BL) questionnaires. BL results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. The BL questionnaire items were scored by calculating the average response to all answered items. Items were graded 1=”stark” (affliction is strong) to 4=”gar nicht” (not present). The higher the BL score, the less afflictions were present for a participant. Baseline is defined as Week 0.</description>
        <time_frame>At Baseline (Week 0) and Weeks 16, 24 and 48</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Beschwerdeliste Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 16, 24 and 48</title>
          <description>Psychiatric assessment were performed using Beschwerdeliste (BL) questionnaires. BL results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. The BL questionnaire items were scored by calculating the average response to all answered items. Items were graded 1=”stark” (affliction is strong) to 4=”gar nicht” (not present). The higher the BL score, the less afflictions were present for a participant. Baseline is defined as Week 0.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2 ,BL, BS (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.4"/>
                    <measurement group_id="O2" value="3.4" spread="0.5"/>
                    <measurement group_id="O3" value="3.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BL,W4 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.7"/>
                    <measurement group_id="O2" value="3.3" spread="0.4"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="3.8">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BL, W8 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.7"/>
                    <measurement group_id="O2" value="3.6" spread="0.5"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BL, W12 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.7"/>
                    <measurement group_id="O2" value="3.3" spread="0.5"/>
                    <measurement group_id="O3" value="3.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BL,W24 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.6"/>
                    <measurement group_id="O2" value="3.2" spread="0.4"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2, BL,W48 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.4"/>
                    <measurement group_id="O2" value="3.4" spread="0.4"/>
                    <measurement group_id="O3" value="3.2">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="4.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BL,BS(n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.4"/>
                    <measurement group_id="O2" value="3.3" spread="0.4"/>
                    <measurement group_id="O3" value="3.2" spread="0.2"/>
                    <measurement group_id="O4" value="3.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BL,W4 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.6"/>
                    <measurement group_id="O2" value="3.0" spread="0.4"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BL,W8 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.6"/>
                    <measurement group_id="O2" value="3.0" spread="0.5"/>
                    <measurement group_id="O3" value="2.6" spread="0.3"/>
                    <measurement group_id="O4" value="3.7">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3, BL,W12 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.6"/>
                    <measurement group_id="O2" value="3.1" spread="0.5"/>
                    <measurement group_id="O3" value="3.2" spread="0.3"/>
                    <measurement group_id="O4" value="3.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BL,W24 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.5"/>
                    <measurement group_id="O2" value="3.2" spread="0.5"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BL,W48 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.4"/>
                    <measurement group_id="O2" value="3.5" spread="0.4"/>
                    <measurement group_id="O3" value="3.4" spread="0.5"/>
                    <measurement group_id="O4" value="3.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory Mean Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 4, 8, 12, 24 and 48</title>
        <description>For the psychiatric assessment, the results of the Beck Depression Inventory (BDI) questionnaires were evaluated. BDI results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. BDI is 21 item participant rated inventory evaluates depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicates more depression. Mean scores are presented by visit. Baseline is defined as Week 0.</description>
        <time_frame>At Baseline (Week 0) and Weeks 4, 8, 12, 24 and 48</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory Mean Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 4, 8, 12, 24 and 48</title>
          <description>For the psychiatric assessment, the results of the Beck Depression Inventory (BDI) questionnaires were evaluated. BDI results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. BDI is 21 item participant rated inventory evaluates depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicates more depression. Mean scores are presented by visit. Baseline is defined as Week 0.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2,BDI,BS (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="4.0"/>
                    <measurement group_id="O2" value="5.4" spread="6.4"/>
                    <measurement group_id="O3" value="9.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BDI,W4 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="12.5"/>
                    <measurement group_id="O2" value="8.8" spread="9.7"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="3.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BDI,W8 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="9.9"/>
                    <measurement group_id="O2" value="3.0" spread="4.2"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BDI,W12 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="9.9"/>
                    <measurement group_id="O2" value="8.5" spread="7.8"/>
                    <measurement group_id="O3" value="8.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BDI,W24 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="9.4"/>
                    <measurement group_id="O2" value="7.6" spread="4.7"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2,BDI,W48 (n=14,13,3,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.3"/>
                    <measurement group_id="O2" value="4.0" spread="5.1"/>
                    <measurement group_id="O3" value="4.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="1.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BDI,BS (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="6.4"/>
                    <measurement group_id="O2" value="8.9" spread="7.7"/>
                    <measurement group_id="O3" value="8.0" spread="5.5"/>
                    <measurement group_id="O4" value="7.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BDI,W4 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="8.4"/>
                    <measurement group_id="O2" value="10.8" spread="8.1"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BDI,W8 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="8.5"/>
                    <measurement group_id="O2" value="12.7" spread="11.6"/>
                    <measurement group_id="O3" value="20.0">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BDI,W12 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="7.3"/>
                    <measurement group_id="O2" value="11.4" spread="8.0"/>
                    <measurement group_id="O3" value="4.8" spread="5.3"/>
                    <measurement group_id="O4" value="15.0" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BDI,W24 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="7.6"/>
                    <measurement group_id="O2" value="9.0" spread="7.9"/>
                    <measurement group_id="O3" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                    <measurement group_id="O4" value="NA">Not Available. The Protocol (and therefore the SAP) had not planned an assessment for this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,BDI,W48 (n=101,97,18,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="4.7"/>
                    <measurement group_id="O2" value="6.7" spread="8.0"/>
                    <measurement group_id="O3" value="5.4" spread="7.7"/>
                    <measurement group_id="O4" value="6.6" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Viral Response</title>
        <description>Time to viral response was calculated as Date of first negative PCR result after screening – date of PCR screening sample + 1 [in days]. Mean of number of days to viral response for overall population were reported.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Standard analysis population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon/Ribavirin 800 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon/Ribavirin 400 mg (24 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon/Ribavirin 800 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon/Ribavirin 400 mg (16 Weeks)</title>
            <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Viral Response</title>
          <description>Time to viral response was calculated as Date of first negative PCR result after screening – date of PCR screening sample + 1 [in days]. Mean of number of days to viral response for overall population were reported.</description>
          <population>Standard analysis population includes all randomized participants.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.1" spread="73.6"/>
                    <measurement group_id="O2" value="165.0" spread="78.8"/>
                    <measurement group_id="O3" value="114.5" spread="76.7"/>
                    <measurement group_id="O4" value="122.8" spread="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2667</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.6290</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9891</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 48</time_frame>
      <desc>An adverse event was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ribavirin 800 mg/24W</title>
          <description>Eligible participants were administered peginterferon alfa-2a (PEG-IFNα-2a) 180 microgram (mcg) subcutaneously (SC) once weekly + Ribavirin 800 milligram (mg) orally daily for 24 weeks (W). The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="E2">
          <title>Ribavirin 400 mg/24W</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 24 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="E3">
          <title>Ribavirin 800 mg/16W</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 800 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
        </group>
        <group group_id="E4">
          <title>Ribavirin 400 mg/16W</title>
          <description>Eligible participants were administered PEG-IFNα-2a 180 mcg SC once weekly + Ribavirin 400 mg orally daily for 16 W. The untreated Follow-up was for 24 W.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy hilar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Renal anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Darier's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis of arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pilonidal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Right otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Salmonella infection nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Septic phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Staphylococcus aureus septicemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anterior cruciate ligament tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Opiate toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar disc herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cerebral oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Epileptic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Ophthalmic migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Seizure cerebral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute and transient psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dependence on opiates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pregnancy of partner</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast cosmetic surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite lost</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cephalgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Exanthema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Seborrheic eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

